Pulmonary Arterial Hypertension Market Poised for Steady Growth Through 2036 Amid Treatment Paradigm Shifts | Thelansis

The Pulmonary Arterial Hypertension (PAH) treatment landscape is entering one of its most active periods in over a decade. With a wave of late-breaking clinical data unveiled at major pulmonology conferences in 2026, an expanding pipeline of oral and biologic therapies, and growing physician confidence in disease-modifying approaches, PAH is shifting from a purely symptom-management model toward long-term risk reduction.
A newly published report, Pulmonary Arterial Hypertension (PAH) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast (2026-2036), offers a complete view of where this market stands today and where it's headed across the 8 major markets (US, EU4, UK, Japan, and China).

Request a free sample of Thelansis' Pulmonary Arterial Hypertension (PAH) Market Outlook and Forecast Report to secure the complete 2026-2036 forecast, exclusive KOL insights, and competitive pipeline data across the 8 Major Markets: https://thelansis.com/reports/pulmonary-arterial-hypertension-pah-market-outlook-forecast-2026-to-2036/

Executive Summary
PAH remains a rare but high-burden pulmonary vascular disease, and despite steady progress in therapeutics, patients on maximal background therapy still face substantial risk of hospitalization, transplantation, or death
2026 has already delivered two headline developments: an expanded FDA approval for an activin-signaling inhibitor based on outcomes data, and positive Phase III results for a next-generation oral prostacyclin receptor agonist
The report captures how these advances, alongside a maturing pipeline, are expected to influence diagnosis rates, treatment sequencing, and overall market value across the 8MM (including China) through 2036
China is emerging as a market to watch, with rising awareness, expanding specialist networks, and gradual improvements in access to advanced PAH therapies

Key Emerging Players
Merck - its activin-signaling inhibitor recently received an expanded label after Phase III outcomes data showed a substantial reduction in the risk of major morbidity and mortality events when added to background therapy in functional class III/IV patients
United Therapeutics - reported positive pivotal Phase III results for its investigational once-daily oral prostacyclin receptor agonist, meeting its primary endpoint with a significant reduction in clinical worsening risk; a regulatory filing is expected in the second half of 2026
FDA granted Orphan Drug Designation to Inhibikase Therapeutics' lead candidate, IKT-001, for the treatment of Pulmonary Arterial Hypertension (PAH). Currently, being evaluated in the global Phase 3 IMPROVE-PAH trial.
Additional companies advancing PAH-focused pipelines include Insmed, Gossamer Bio, Cereno Scientific, Chugai Pharmaceutical, Janssen, AstraZeneca, and several clinical-stage biotechs exploring novel mechanisms beyond the traditional three-pathway approach
The report profiles these players in detail, benchmarking pipeline stage, mechanism of action, and expected market entry timelines

Request a sample report for an in-depth analysis of key emerging players, pipeline staging, and mechanisms of action in Pulmonary Arterial Hypertension (PAH): https://thelansis.com/reports/pulmonary-arterial-hypertension-pah-market-outlook-forecast-2026-to-2036/?utm_source=openpr&utm_medium=pressrelease&utm_campaign=pah_mo

Key Current Therapies or Standard of Care
Treatment continues to center around three established pathways: endothelin receptor antagonists, PDE-5 inhibitors, and prostacyclin pathway agents, often used in combination
Activin-signaling inhibition has emerged as a newer, add-on approach shown to meaningfully lower the risk of clinical worsening events on top of standard background therapy
Upfront combination therapy is increasingly favored by treating physicians over sequential escalation, reflecting a shift toward earlier, more aggressive risk mitigation
The report maps how these regimens vary by region and functional class, and how newer agents are expected to reposition existing standards of care

Key Market Drivers/Trends
A steady stream of positive late-stage trial readouts in 2026 is renewing commercial and investor interest in PAH as a therapeutic category
Oral, once-daily formulations are gaining favor over infused or inhaled options, driven by patient convenience and improved adherence
Growing emphasis on biomarker-driven monitoring (e.g., NT-proBNP) and functional capacity outcomes is shaping how new therapies are positioned and reimbursed
China's PAH market is benefiting from expanding specialist referral networks and gradual alignment with global treatment guidelines, positioning it as a meaningful growth contributor within the 8MM
The report quantifies these dynamics with a full 2026-2036 forecast, segmented by country, therapy class, and patient population

Translate these macro drivers into a competitive advantage. Request the Thelansis Pulmonary Arterial Hypertension (PAH) sample report to unlock granular pipeline analysis, deal tracking, and market forecasts: https://thelansis.com/reports/pulmonary-arterial-hypertension-pah-market-outlook-forecast-2026-to-2036/?utm_source=openpr&utm_medium=pressrelease&utm_campaign=pah_mo

Key Unmet Need & KOL Expectations
Even with maximal background therapy, a meaningful proportion of PAH patients continue to experience disease progression, underscoring the need for therapies that go beyond symptom control
Leading pulmonary hypertension specialists have pointed out that the risk of hospitalization, transplantation, or death remains unacceptably high for many patients despite current treatment options
There is strong clinical interest in agents that act on the underlying vascular remodeling process, rather than solely managing hemodynamic symptoms
Diagnostic delay remains a persistent challenge, particularly outside the US and Western Europe, reinforcing calls for earlier screening and referral pathways

Commercial Opportunity
The convergence of an aging at-risk population, improved diagnostic awareness, and a stronger late-stage pipeline sets up meaningful commercial upside for PAH across the 8MM through 2036
Disease-modifying and outcomes-focused therapies are expected to command premium positioning as payers and physicians shift focus from symptom management to long-term risk reduction
China represents a distinct growth opportunity, with rising treatment rates and improving access infrastructure over the forecast period
Companies with differentiated mechanisms, oral convenience, or strong outcomes data are best positioned to capture share as the competitive landscape becomes more crowded

Access the complete Pulmonary Arterial Hypertension (PAH) market outlook and forecast report to explore the evolving market and future commercial opportunities: https://thelansis.com/reports/pulmonary-arterial-hypertension-pah-market-outlook-forecast-2026-to-2036/?utm_source=openpr&utm_medium=pressrelease&utm_campaign=pah_mo

CONTACT:
Himanshi Negi
Manager - Global BD and Partnering
Thelansis Knowledge Partners LLP
Email: n.himanshi@thelansis.com
Phone: +91-9560149525
Website: www.thelansis.com
Reach us at: clientsupport@thelansis.com

ABOUT THELANSIS:
Thelansis is a global healthcare market intelligence company providing strategic insights to global pharmaceutical, biotechnology, and life sciences organizations. Through proprietary epidemiology models, primary research, physician interviews, payer analysis, and commercial forecasting, Thelansis enables organizations to make informed decisions across product development, market access, and commercialization.
In addition, Thelansis offers EpiLansis, an AI-powered cloud intelligence platform that enables interactive exploration of patient populations, epidemiology trends, treatment utilization, and market dynamics across multiple therapeutic areas.
For more information about Thelansis and its disease intelligence solutions, visit www.thelansis.com or contact the team at clientsupport@thelansis.com.

This release was published on openPR.